Effect of Prebiotics on Blood Pressure Management

Launched by SUN YAT-SEN UNIVERSITY · May 3, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a supplement made from highland barley, called β-glucan, may help manage blood pressure, improve gut health, and reduce the risk of heart problems in people with high blood pressure, also known as hypertension. The study will involve participants who are between 30 and 65 years old and have been newly diagnosed with high blood pressure or have blood pressure readings of 140/90 mmHg or higher. Participants should not be taking blood pressure medications and should have a body mass index (BMI) of at least 18.

If you meet these criteria, you might be eligible to take part in this trial. It's important to note that certain health conditions, such as severe liver or kidney problems, autoimmune diseases, or recent gastrointestinal issues, may prevent you from joining. Participants will be monitored throughout the study, and they can expect to learn more about how diet and gut health might influence blood pressure. The trial is not yet recruiting participants, so there is still time to consider your options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age:30-65 years old
• • 2. Newly diagnosed hypertension did not use antihypertensive drugs OR Systolic blood pressure ≥140mmHg on the physical examination OR Diastolic blood pressure ≥90mmHg on the physical examination.
• • 3. BMI≥18 kg/m2
• Exclusion Criteria:
• • 1. Receiving or have been treated with antihypertensive drugs.
• • 2. Complications including cardiovascular and cerebrovascular diseases such as coronary heart disease and stroke.
• • 3. Severe liver or renal insufficiency (alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase is greater than 3 times the upper limit of normal OR GFR\<30ml/min/1.73m2).
• • 4. Autoimmune diseases or thyroid diseases.
• • 5. Women who are pregnant, nursing, or prepare to give birth during the trail.
• • 6. Malignant disease, infectious disease, inflammatory disease and advanced liver disease.
• • 7. Mental or intellectual abnormalities, unable to sign informed consent.
• • 8. Complications including chronic gastrointestinal disease; or suffered from acute gastrointestinal diseases within 1 months before screening visit.
• • 9. Received antibiotics, probiotics within 3 months before screening visit or throughout the trail.
• • 10. Major operations were performed within six months of screening visit, or will be made during the trial.
• • 11. Alcohol abuse (alcohol intake\>60g/d for male and alcohol intake\>40g/d for female)